Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice

Fig. 3

Survival probability plots, for drug retention in patients with ankylosing spondylitis starting a first TNFi 2006–2015. a Comparing the five different available TNFi, used as the first ever TNFi. b Comparing the first, second and third TNFi, with hazard ratios for TNFi discontinuation also adjusted for sex and age at the respective treatment start. TNFi = tumour necrosis factor alpha inhibitor; ADA = adalimumab; CER = certolizumab pegol; ETN = etanercept; GOL = golimumab; IFX = infliximab

Back to article page